Senseonics Holdings (SENS) Aktienübersicht
Senseonics Holdings, Inc. ist ein Medizintechnikunternehmen, das sich auf die Entwicklung und Herstellung von Systemen zur kontinuierlichen Glukoseüberwachung (CGM) für Diabetiker in den Vereinigten Staaten und international konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
SENS Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Senseonics Holdings, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$5.40 |
| 52-Wochen-Hoch | US$11.58 |
| 52-Wochen-Tief | US$4.79 |
| Beta | 0.97 |
| 1 Monat Veränderung | -1.55% |
| 3 Monate Veränderung | 0.65% |
| 1 Jahr Veränderung | -46.66% |
| 3 Jahre Veränderung | -67.23% |
| 5 Jahre Veränderung | -91.13% |
| Veränderung seit IPO | -91.70% |
Aktuelle Nachrichten und Updates
Seeking Alpha • Jul 14
Senseonics: Implantable Sensor, Unsustainable Spend
Summary Senseonics Holdings is a Sell, with persistent concerns about cash burn, dilution, and lack of profitability. SENS's direct-to-consumer strategy and in-house commercialization have driven high SG&A, with 2026 cash burn projected up to $120 million on $60–64 million revenue. Gross margins improved to 58% in Q1, but sustained growth remains highly dependent on heavy investment and infrastructure buildout. Pipeline products Gemini (2027) and Freedom (2028) could boost adoption, but no near-term inflection in revenue/opex is evident. Read the full article on Seeking Alpha
Narrative-Update • Jul 14
SENS: Future Margins And Revenue Mix Will Drive Upside Potential
The analyst price target for Senseonics Holdings has been revised lower by several dollars per share. Analysts cite updated assumptions on fair value, revenue growth, profit margins, and a reduced future P/E multiple as the key drivers of this change.
Narrative-Update • Jun 30
SENS: Long-Duration CGM Data Will Support Future Margin Upside
Senseonics Holdings' updated analyst price target has moved lower by about $5.10 to $13.80, as analysts factor in revised expectations for fair value, revenue growth, profit margins, and future P/E assumptions following recent target cuts from several firms. Analyst Commentary Recent research updates on Senseonics Holdings focus on how its current trading level compares with revised views on fair value, revenue potential, profitability, and assumed P/E multiples.
Narrative-Update • Jun 16
SENS: Long Wear CGM Execution Will Support Future Profitability Repricing Potential
Analysts have trimmed their average price target on Senseonics Holdings stock by a few dollars, citing updated expectations that reflect modest adjustments to revenue growth, profit margin, discount rate, and future P/E assumptions. Analyst Commentary Recent research updates on Senseonics Holdings highlight that even with lower price targets, some bullish analysts still see potential drivers that they believe could support the stock if the company executes on its plans.Recent updates
Seeking Alpha • Jul 14
Senseonics: Implantable Sensor, Unsustainable Spend
Summary Senseonics Holdings is a Sell, with persistent concerns about cash burn, dilution, and lack of profitability. SENS's direct-to-consumer strategy and in-house commercialization have driven high SG&A, with 2026 cash burn projected up to $120 million on $60–64 million revenue. Gross margins improved to 58% in Q1, but sustained growth remains highly dependent on heavy investment and infrastructure buildout. Pipeline products Gemini (2027) and Freedom (2028) could boost adoption, but no near-term inflection in revenue/opex is evident. Read the full article on Seeking AlphaNarrative-Update • Jul 14
SENS: Future Margins And Revenue Mix Will Drive Upside Potential
The analyst price target for Senseonics Holdings has been revised lower by several dollars per share. Analysts cite updated assumptions on fair value, revenue growth, profit margins, and a reduced future P/E multiple as the key drivers of this change.Narrative-Update • Jun 30
SENS: Long-Duration CGM Data Will Support Future Margin Upside
Senseonics Holdings' updated analyst price target has moved lower by about $5.10 to $13.80, as analysts factor in revised expectations for fair value, revenue growth, profit margins, and future P/E assumptions following recent target cuts from several firms. Analyst Commentary Recent research updates on Senseonics Holdings focus on how its current trading level compares with revised views on fair value, revenue potential, profitability, and assumed P/E multiples.Narrative-Update • Jun 16
SENS: Long Wear CGM Execution Will Support Future Profitability Repricing Potential
Analysts have trimmed their average price target on Senseonics Holdings stock by a few dollars, citing updated expectations that reflect modest adjustments to revenue growth, profit margin, discount rate, and future P/E assumptions. Analyst Commentary Recent research updates on Senseonics Holdings highlight that even with lower price targets, some bullish analysts still see potential drivers that they believe could support the stock if the company executes on its plans.Narrative-Update • Jun 02
SENS: Long Wear CGM Execution Will Drive Future Profitability And Repricing
The analyst price target for Senseonics Holdings has been reduced by $11, with analysts citing updated fair value estimates, a lower future P/E assumption, and recent Street research that reset targets at H.C. Wainwright, Stifel, and Lake Street. Analyst Commentary Recent Street research on Senseonics Holdings points to a reset in price targets that reflects updated fair value work, revised P/E assumptions, and refreshed views on execution risk and potential growth.Narrative-Update • May 17
SENS: Long Wear CGM Adoption Will Drive Future Profitability And Repricing
Senseonics Holdings' consensus analyst price target has been reduced by several dollars, with analysts citing updated assumptions for revenue growth, profitability, and valuation multiples as key reasons for the lower fair value outlook. Analyst Commentary Even with the recent cuts to price targets, bullish analysts still see potential for Senseonics Holdings to create value if the company executes on its growth and profitability plans.Narrative-Update • Apr 29
SENS: Long Wear CGM Adoption And AID Integration Will Drive Upside
Analysts have slightly adjusted their price target for Senseonics Holdings to $31.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E multiples, while keeping the overall fair value view steady. What's in the News First European launch of the Eversense 365 CGM system, described as the world’s first and only one year CGM, starting with patients in Sweden and with rollouts planned in Germany, Spain and Italy in the coming weeks (Key Developments).Narrative-Update • Apr 13
SENS: Real World CGM Use And AID Access Will Drive Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing updated assumptions that now reflect slightly different discount rate, revenue growth, profit margin, and future P/E inputs in their models. What's in the News The board is asking stockholders to approve a change to the Certificate of Incorporation to increase authorized common shares to 140,000,000 from 70,000,000, with the meeting set for May 20, 2026 (Key Developments).Narrative-Update • Mar 30
SENS: Long-Duration CGM Data Will Support Future Automated Delivery Upside
Analysts have modestly adjusted their price target on Senseonics Holdings to $18.92, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value view steady. What's in the News New real world evidence data for the Eversense 365 CGM system reports an average transmitter wear time of 93.8% over one year, a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66% across 5,059 sensors used in the US, with over 75% of users reaching hypoglycemic targets (Key Developments).Narrative-Update • Mar 16
SENS: Real World CGM Outcomes And AID Adoption Will Support Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing slightly higher assumed discount rates, a modest adjustment in expected revenue growth and profit margins, and a small shift in future P/E assumptions as the main factors behind their updated view. What's in the News New real world evidence data on more than 5,000 Eversense 365 sensors in US patients showed high adherence, a mean Glucose Management Indicator of 7.14% and Time in Range of 66%, with over 75% of users meeting hypoglycemia targets across a full year of use (Key Developments).Narrative-Update • Mar 02
SENS: Long-Duration CGM Access Will Drive Future Automated Delivery Upside
Analysts have modestly adjusted their price target on Senseonics Holdings to $18.92 per share. This reflects slightly different assumptions on discount rate, revenue growth, profit margin and future P/E, while keeping their overall valuation view broadly unchanged.Narrative-Update • Feb 16
SENS: Internalized Commercial Model And AID Launch Will Drive Long-Term Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing largely unchanged fair value assumptions, along with small adjustments to the discount rate, revenue growth, profit margin, and future P/E inputs. What's in the News Senseonics issued 2026 guidance, with expected full year global net revenue of about US$58 million to US$62 million, linked to the planned transition of Eversense commercialization from Ascensia starting January 1, 2026 (Corporate guidance).Narrative-Update • Feb 02
SENS: Long-Duration CGM Execution Risk Will Set Up Future Upside Potential
Analysts have trimmed their 12 month target on Senseonics to US$15 from US$25, citing updated sales multiples on 2028 estimates and a higher 12% discount rate to reflect commercial execution risk following the recent stock split. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential at US$15, even after trimming the target from US$25.Narrative-Update • Jan 18
SENS: Long-Duration CGM Share Gains Will Support Future Upside Potential
Analysts have trimmed their average price target on Senseonics to about $18.92. This reflects updated models that factor in lower sales multiples, a roughly 12% discount rate to account for commercial execution risk, and expectations around future product adoption and capital needs.Analyseartikel • Jan 13
Senseonics Holdings, Inc.'s (NASDAQ:SENS) Share Price Could Signal Some Risk
You may think that with a price-to-sales (or "P/S") ratio of 9.9x Senseonics Holdings, Inc. ( NASDAQ:SENS ) is a stock...Narrative-Update • Jan 04
SENS: Internalized Commercial Model Will Drive Long Term Upside Potential
Analysts have trimmed their price target on Senseonics Holdings to $15.00 from $25.00, citing updated long term growth assumptions, a higher perceived discount rate to reflect commercial execution risk, and the need for additional capital as the company internalizes commercial operations despite favorable physician feedback on Eversense and Gemini. Analyst Commentary Bullish analysts acknowledge the reduced price targets but emphasize that the stock still offers meaningful upside from current levels, with valuation supported by long term revenue growth expectations for Eversense and the upcoming Gemini platform.Narrative-Update • Dec 21
SENS: Long-Duration CGM Share Gains Will Drive Future Upside Potential
Analysts have modestly reduced their price target on Senseonics Holdings to $15 from $25, reflecting updated sales multiple assumptions, a higher discount rate to account for commercial execution risk, and a more cautious view on funding needs as the company prepares to take commercial operations back in house. Analyst Commentary Street research reflects a mixed but engaged view on Senseonics, with valuation resets largely tied to updated sales assumptions, perceived execution risk, and the capital intensity of bringing commercialization back in house.Analyseartikel • Dec 09
Is Senseonics Holdings (NASDAQ:SENS) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative-Update • Dec 07
SENS: Long-Duration CGM Share Gains Will Drive Future Upside Potential
Analysts have modestly reduced their average price target for Senseonics Holdings to about $18.92 per share from roughly $25.00. They cite recalibrated sales multiples, a slightly higher risk premium around commercial execution, and the need for additional capital as the company internalizes commercialization and invests in next-generation sensor platforms.Narrative-Update • Nov 23
SENS: Market Share Gains Will Drive Long-Term Revenue Expansion
Analysts have revised their price target for Senseonics Holdings lower. They note that updated sales estimates and higher perceived commercial risk have led to a reduction from approximately $25 to below $19 per share.Narrative-Update • Nov 03
SENS: Future Commercial Rollout Will Drive Diabetes Monitoring Adoption
Analysts have revised their price target for Senseonics Holdings downward from $28.60 to $25.33 per share, citing expected financial impacts from the company's assumption of commercial operations. This is balanced by continued optimism over the Eversense 365 system's market potential.Narrative-Update • Oct 20
Continuous Glucose Monitoring Will Redefine Preventive Diabetes Care
Analysts have significantly increased their price target for Senseonics Holdings from $1.43 to $28.60. They cite growing confidence in the company's expanding product offerings and anticipated demand for its Eversense 365 sensor system.Narrative-Update • Aug 08
Continuous Glucose Monitoring Will Redefine Preventive Diabetes Care
The downward revision in Senseonics Holdings’ price target reflects a combination of lowered future earnings multiples and a higher discount rate, resulting in the consensus fair value estimate declining from $1.55 to $1.41. What's in the News Senseonics Holdings completed a $50 million follow-on equity offering, issuing 100 million common shares at $0.50 per share with a $0.03 discount.
Neues Narrative • Mar 28
Eversense 365 Will Expand Patient Access With EU Launch
U.S. launch and future EU expansion of Eversense 365 could drive revenue growth through increased adoption and international market presence.Aktionärsrenditen
| SENS | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 9.9% | 2.3% | 2.4% |
| 1Y | -46.7% | -12.8% | 19.6% |
Rendite im Vergleich zur Industrie: SENS unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -12.8% erzielte.
Rendite vs. Markt: SENS hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 19.6 erzielte.
Preisvolatilität
| SENS volatility | |
|---|---|
| SENS Average Weekly Movement | 9.2% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: SENS hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: SENSDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 130 | Tim Goodnow | www.senseonics.com |
Senseonics Holdings, Inc. ist ein Medizintechnikunternehmen im kommerziellen Stadium, das sich auf die Entwicklung und Herstellung von Systemen zur kontinuierlichen Glukosemessung (CGM) für Menschen mit Diabetes in den Vereinigten Staaten und international konzentriert. Zu den Produkten des Unternehmens gehören Eversense, Eversense XL, Eversense E3 und Eversense 365. Dabei handelt es sich um implantierbare CGM-Systeme zur Messung des Blutzuckerspiegels bei Diabetikern mittels eines unter der Haut getragenen Sensors, eines abnehmbaren und wiederaufladbaren intelligenten Senders und einer App für die Diabetesüberwachung und -verwaltung in Echtzeit.
Senseonics Holdings, Inc.'s Grundlagenzusammenfassung
| SENS grundlegende Statistiken | |
|---|---|
| Marktanteil | US$272.76m |
| Gewinn(TTM) | -US$87.19m |
| Umsatz(TTM) | US$40.71m |
6.9x
Kurs-Umsatz-Verhältnis-3.2x
Kurs-Gewinn-Verhältnis Ist SENS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| SENS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$40.71m |
| Kosten der Einnahmen | US$19.51m |
| Bruttogewinn | US$21.20m |
| Sonstige Ausgaben | US$108.39m |
| Gewinn | -US$87.19m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 06, 2026
| Gewinn per Aktie (EPS) | -1.67 |
| Bruttomarge | 52.07% |
| Nettogewinnspanne | -214.16% |
| Schulden/Eigenkapital-Verhältnis | 104.6% |
Wie hat sich SENS auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/04 02:41 |
| Aktienkurs zum Tagesende | 2026/08/04 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Senseonics Holdings, Inc. wird von 16 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Matthew Miksic | Barclays |
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |